Oslo, Norway, 22 February 2012 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces that senior management will participate in the following life sciences investor conferences:
Citi 2012 Global Health Care Conference
Date: 27 & 28 February 2012
Participants: Gillies O'Bryan-Tear (CMO) & Mike Booth (IR)
Presentation time: 1.30pm EDT, 27 February
Venue: Waldorf Astoria Hotel, New York City, USA
Credit Suisse Healthcare One-on-One Conference 2012
Date: 1 & 2 March 2012
Participants: Thomas Ramdahl (CTO), Øystein Soug (CFO) & Mike Booth (IR)
Venue: Credit Suisse, 1 Cabot Square, London, UK
Bernstein Emerging Biotech Conference 2012
Date: 12-14 March 2012
Participants: Thomas Ramdahl (CTO)
Presentation time: 4.30pm MT, 14 March
Venue: Snowbird, Utah, USA
Presentations will be available to download at www.algeta.com (http://www.algeta.com/) following these events.
For further information, please contact
| Mike Booth|
Communications & Corporate Affairs
| +47 2202 4510|
| International media enquiries:|
Citigate Dewe Rogerson
| +44 207 638 9571|
| US investor enquiries:|
The Trout Group
| +1 646 378 2928|
Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform.
Algeta's lead product Alpharadin (radium-223 chloride) is in development as a potential new treatment for cancer patients with bone metastases. It is in pre-registration for castration-resistant prostate cancer (CRPC) patients with bone metastases, and filings are expected mid 2012 in the USA and Europe; Alpharadin has Fast Track designation for this indication in the USA.
Alpharadin is also under clinical investigation in breast cancer patients with bone metastases and in combination with docetaxel chemotherapy in CPRC patients with bone metastases.
Alpharadin is being developed and will be commercialized, pending approval, under a global agreement with Bayer Pharma AG.
Algeta is also exploring the potential of Targeted Thorium Conjugates (TTCs), which are based on conjugating the alpha-emitter thorium-227 to targeting molecules, as a basis of a future pipeline of tumor-targeting alpha-pharmaceutical candidates.
The Company is headquartered in Oslo, Norway, and is listed on the Oslo Stock Exchange (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
This news release contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. Such forward-looking statements reflect our current views and are based on the information currently available to Algeta. Algeta cannot give any assurance to the correctness of such statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. These factors include, among other things, risks or uncertainties associated with the success of future clinical trials, collaborations with other companies in the development of targeting molecules and alpha particle payloads, risks associated with technological development, growth management, general economic and business conditions and the pricing environment, the impact of competition, the ability to successfully commercialize Alpharadin and our other products, the risk that research & development will not yield new products that achieve commercial success, manufacturing capacity, the risk of non-approval of patents not yet granted, risks in obtaining regulatory approvals for Alpharadin and our other products as well as the expected timing of filings for regulatory approvals, and difficulties of obtaining relevant governmental approvals for new products, and the other risks and uncertainties described in our annual report.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Algeta ASA via Thomson Reuters ONE